Verastem    Print Page | Close Window

2018 News Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
01/04/18Verastem Announces Increased Hercules Debt Facility
Increases Borrowing Limit to $50 Million Over the Next 15 Months, Through Potential Approval and Commercial Launch of Duvelisib BOSTON--(BUSINESS WIRE)--Jan. 4, 2018-- Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced its entry into an amendment to its Loan and Security Agreement with Hercules Capital, Inc., increasing its existing borrowing ... 
Printer Friendly Version
01/04/18Verastem Appoints Joseph Lobacki as Chief Commercial Officer
BOSTON--(BUSINESS WIRE)--Jan. 4, 2018-- Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Joseph Lobacki as Executive Vice President and Chief Commercial Officer. Mr. Lobacki, formerly Chief Commercial Officer of Medivation, will be responsible for overseeing the commercial strategy and execution for Verastem’s lead product candidate... 
Printer Friendly Version